Browsing by Author "Ebrahim Variava"

Now showing 1 - 13 of 13

Assessing potential drugdrug interactions between clofazimine and other frequently used agents to treat drugresistant tuberculosis
(AMER SOC MICROBIOLOGY) Allan Kengo; Firdaus Nabeemeeah; P Denti; Ryan Sabet; Gifty Okyere-Manu; E et al; Neil Martinson; Ebrahim Variava
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicinresistant tuberculosis a crosssectionaland longitudinal study
(ELSEVIER SCIENCE INC) Nazir Ismail; S Omar; H Moultrie; Zaheda Bhyat; Francesca CONRADIE; M Enwerem; Ebrahim Variava; E et al
CompaRISON OF QuantiFERON Glod inTube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy among Patients Newly Diagnosed with HIV in the North West Province of South Africa the Teko Study A Cluster Randomized Trial
(OXFORD UNIV PRESS INC) Brooke A Jarrett; K Shearer; Katlego Mothlaoleng; S Chon; E et al; Limakatso Lebina; Neil Martinson; Ebrahim Variava
Coronavirus Host Genomics Study: South Africa (COVIGen-SA)
(2022-10-06) Andrew K. May; Heather Seymour; Harriet Etheredge; Heather Maher; Marta C. Nunes; ShabirA.Madhi; SimisoM. Sokhela; W. D. FrancoisVenter; Neil Martinson; Firdaus Nabeemeeah; Cheryl Cohen; Jocelyn Moyes; Sibongile Walaza; Stefano Tempia; Jackie Kleynhans; Anne von Gottberg; Jeremy Nel; Halima Dawood; Ebrahim Variava; Stephen Tollman; Kathleen Kahn; KobusHerbst; EmilyB.Wong; CarolineT.Tiemessen; Alex van Blydenstein; Lyle Murray; Michelle Venter; June Fabian; Miche´le Ramsay
However, continental Africans are yet to be adequately represented in such studies despite the importance of genetic factors in understanding Africa’s response to the pandemic. We describe the development of a research resource for coronavirus host genomics studies in South Africa known as COVIGen-SA—a multicollaborator strategic partnership designed to provide harmonised demographic, clinical, and genetic information specific to Black South Africans with COVID-19. Over 2,000 participants have been recruited to date. Preliminary results on 1,354 SARS-CoV-2 positive participants from four participating studies showed that 64.7% were female, 333 had severe disease, and 329 were people living with HIV. *rough this resource, we aim to provide insights into host genetic factors relevant to African-ancestry populations, using both genome-wide association testing and targeted sequencing of important genomic loci. *is project will promote and enhance partnerships, build skills, and develop resources needed to address the COVID-19 burden and associated risk factors in South African communities.
D3Penta 21 clinical trial design A randomised noninferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV1 infection aged 2
(ELSEVIER SCIENCE INC) A Turkova; M Chan; C Kityo; A Kekitiinwa; E et al; Avyi Violari; Ebrahim Variava
Epidemiology of Pertussis in Individuals of All Ages Hospitalized With Respiratory Illness in South Africa January 2013December 2018
Nicole Wolter; Cheryl Cohen; Stefano Tempia; Sibongile Walaza; Fahima Moosa; Mignonette Du Plessis; Meredith L McMorrow; Florette Treurnicht; Orienka Hellferscee; Halima Dawood; Ebrahim Variava; Anne Von Gottberg
Estimation of vaccine effectiveness against SARSCoV2associated hospitalization using sentinel surveillance in South Africa
N Chiwandire; Sibongile Walaza; Anne Von Gottberg; Nicole Wolter; Mignonette Du Plessis; Fahima Moosa; Michelle Groome; Jeremy Nel; Ebrahim Variava; H Dawood; Mvuyo Makhasi; L R Feldstein; P Marcenac; E et al; Cheryl Cohen
Hypertension guideline implementation and blood pressure control in Matlosana South Africa
Keolebile Ditlhabolo; Carien Lion-Cachet; Ebrahim Variava
Patient and provider costs of the new BPaL regimen for drugresistant tuberculosis treatment in South Africa A costeffectiveness analysis
Denise Evans; Kamban Hirasen; Clive Ramushu; Lawrence Long; E Sinanovic; Francesca CONRADIE; Pauline Howell; X Padanilam; H Ferreira; Ebrahim Variava; Shakira Rajaram; E et al
Posttrial perceptions of a symptombased TB screening intervention in South Africa implementation insights and future directions for TB preventive healthcare services
Nicole Salazar-Austin; Minja Milovanovic; Nora West; Grace Barnes; Ebrahim Variava; Neil Martinson; Richard Chaisson; E et al
Remote Ischaemic Conditioning in STEMI Patients in SubSaharan AFRICA Rationale and Study Design for the RICAFRICA Trial
(SPRINGER) K Lukhna; D J Hausenloy; A S Ali; A Bajaber; Arthur Mutyaba; Ebrahim Variava; E et al
The attributable fraction of respiratory syncytial virus among patients of different age with influenza-like illness and severe acute respiratory illness in a high HIV prevalence setting, South Africa, 2012-2016 Running title: The attributable fraction of RSV in South Africa (all ages), South Africa 2012- 2016
(2022-11-22) Jocelyn Moyes; Stefano Tempia; Sibongile Walaza; Meredith L. McMorrow; Adam L. Cohen; Florette Treurnicht; Orienka Hellferscee; Nicole Wolter; Anne Von Gottberg; Halima Dawood; Ebrahim Variava; Kathleen Kahn; Shabir A. Madhi; Cheryl Cohen
Introduction The detection of respiratory syncytial virus (RSV) in upper airway samples does not necessarily infer causality of illness. Calculating the attributable fraction (AF) of RSV in clinical syndromes could refine disease burden estimates. Methods Using unconditional logistic regression models, we estimated the AF of RSV-associated influenza-like illness (ILI) and severe-acute respiratory illness (SARI) cases by comparing RSVdetection prevalence among ILI and SARI cases to those of healthy controls in South Africa, 2012-2016. The analysis, stratified by HIV serostatus, was conducted in the age categories <1, 1-4, 5-24, 25-44, 45-64, ≥65 years. Results We included 12,048 individuals: 2,687 controls, 5,449 ILI cases and 5,449 SARI cases. RSVAFs for ILI were significant in <1, 1-4, 5-24, 25-44-year age groups: 84.9%(95% confidence interval (CI) 69.3%-92.6%), 74.6%(95%CI 53.6%-86.0%), 60.8%(95%CI 21.4%-80.5%) and 64.1%(95%CI 14.9%-84.9%), respectively. Similarly, significant RSV-AFs for SARI were 95.3%(95%CI 91.1%-97.5) and 83.4%(95%CI 70.9-90.5) in the <1 and 1-4-year age groups respectively. In HIV-infected persons, RSV was significantly associated with ILI cases versus controls in individuals aged 5-44 years. Conclusion High RSV-AFs in young children confirm RSV detection is associated severe respiratory illness in South African children, specifically infants. These estimates will assist with refining burden estimates and cost effectiveness models
The economic burden of RSV-associated illness in children aged < 5 years, South Africa 2011–2016.
(2022-06-21) Jocelyn Moyes; Stefano Tempia; Sibongile Walaza; Meredith L. McMorrow3; Florette Treurnicht4 Nicole Wolter; Anne von Gottberg; Kathleen Kahn6; Adam L Cohen; Halima Dawood; Ebrahim Variava; Cheryl Cohen
Introduction Data on the economic burden of RSV-associated illness will inform decisions on the programmatic implementation of maternal vaccines and monoclonal antibodies. We estimated these costs in fine age bands to allow more accurate cost-effectiveness models to account for limited duration of protection conferred by short or long acting interventions. Methods We conducted a costing study at sentinel sites across South Africa to estimate out-of-pocket and indirect costs for RSV-associated mild and severe illness. We collected facility-specific costs for staffing, equipment, services, diagnostic tests and treatment. Using case-based data we calculated a patient day equivalent (PDE) for RSV-associated hospitalisations or clinic visits; the PDE was multiplied by the number of days of care to provide a case-cost to the healthcare system. We estimated the costs in 3-month age intervals in children aged <1 years and as a single group for children aged 1-4 years. We then applied our data to a modified version of the World Health Organization tool for estimating mean annual national cost burden, including medically and non-medically attended RSV-associated illness. Results The estimated mean annual cost of RSV-associated Illness in children aged <5 years was United States dollars ($)137 204 393, of which 81% ($111 742 713) were healthcare system incurred, 6% ($8 881 612) were out of pocket expenses and 13% ($28 225 801) were indirect costs. Thirty-three percent ($45 652 677/$137 204 393) of the total cost in children aged <5 years was in the <3-month age group, of which 52% ($71 654 002) were healthcare system incurred. The costs of non-medically attended cases increased with age from $3 307 218 in the <3-month age group to $8 603 377 in the 9-11-month age group. Conclusion Among children <5 years of age with RSV in South Africa, the highest cost burden was in young infants; therefore, interventions against RSV targeting this age group are important to reduce the health and cost burden of RSV-associated illness.